|
||||||
|
 | |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
|
Gene: ENSG00000186765 |
Summary for FSCN2 |
 Gene summary |
| Gene information | Ensembl ID | ENSG00000186765 | Gene symbol | FSCN2 |
| Gene name | fascin actin-bundling protein 2, retinal | |
| HGNC | 3960 | |
| Entrez ID | 25794 | |
| Gene type | protein_coding | |
| Synonyms | FSCN2|RP30|RFSN | |
| UniProtAcc | O14926 |
| Drugs associated with this gene(DrugBank). |
| Gene ID | Gene Symbol | Drug ID | Drug Name | Drug Type |
| Cancer therapeutic drugs associated with this gene(NCI). |
| Gene ID | Gene Name | Drug ID | Drug Name | Drug Type | Cancer |
Top |
Structure and expression level for FSCN2 |
| AS events and RNA A-to-I editing events of the gene in TCGA based on Genvode V22 structure. ∗For more information on exon skipping events please check the ExonskipDB database. ∗For more information on exon skipping events please check the CAeditome database. |
 |
| Landscape of gene expressions across multiple cancer types. |
 |
| Differentially expressed gene analysis between tumor male and tumor female samples. |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| Differentially expressed gene analysis between tumor male and normal male samples. |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| Differentially expressed gene analysis between tumor female and normal female samples. |
 |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| FSCN2 | 9.28e+01 | 1.05e+00 | 2.05e-01 | 5.14e+00 | 2.76e-07 | 8.87e-07 | LUAD |
Top |
Sex-biased somatic mutation for FSCN2 |
| ∗For more information on exon skipping events please check the ExonskipDB database. |
| Gene ID | Cancer Type | Hugo Symbol | Male | Female | pval | or | ci.up | ci.low | adjPval |
Top |
DNA methylation with beta values for FSCN2 |
| Landscape of DNA methylation across multiple cancer types. |
 |
| Differentially expressed CpG sites between male tumor and female tumor patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| BRCA | cg16201883 | chr17:81528927 | CGI:chr17:81527979-81529265 | promoter,exon,CDS,gene body | 5.92e-01 | 8.29e-01 | -2.68e+00 | 7.47e-03 | 2.39e-02 | -2.37e-01 |
| ACC | cg00221012 | chr17:81528638 | CGI:chr17:81527979-81529265 | promoter,exon,CDS,gene body | 3.99e-01 | 5.18e-01 | -2.07e+00 | 3.86e-02 | 4.53e-02 | -1.19e-01 |
| Differentially expressed CpG sites between male tumor and male normal patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| KIRC | cg00221012 | chr17:81528638 | CGI:chr17:81527979-81529265 | promoter,exon,CDS,gene body | 4.48e-01 | 3.28e-01 | 4.94e+00 | 7.65e-07 | 2.88e-06 | 1.21e-01 |
| LUSC | cg01512532 | chr17:81528013 | CGI:chr17:81527979-81529265 | promoter | 6.39e-01 | 5.01e-01 | 2.89e+00 | 3.88e-03 | 6.76e-03 | 1.38e-01 |
| LUSC | cg16201883 | chr17:81528927 | CGI:chr17:81527979-81529265 | promoter,exon,CDS,gene body | 5.03e-01 | 9.38e-01 | -4.13e+00 | 3.61e-05 | 5.31e-04 | -4.35e-01 |
| LUSC | cg09084279 | chr17:81527980 | CGI:chr17:81527979-81529265 | promoter | 5.07e-01 | 3.91e-01 | 2.40e+00 | 1.65e-02 | 2.05e-02 | 1.16e-01 |
| LUSC | cg00221012 | chr17:81528638 | CGI:chr17:81527979-81529265 | promoter,exon,CDS,gene body | 3.63e-01 | 5.31e-01 | -3.96e+00 | 7.45e-05 | 6.23e-04 | -1.68e-01 |
| COAD | cg16201883 | chr17:81528927 | CGI:chr17:81527979-81529265 | promoter,exon,CDS,gene body | 3.75e-01 | 5.01e-01 | -3.58e+00 | 3.45e-04 | 9.46e-04 | -1.27e-01 |
| LIHC | cg20932150 | chr17:81528242 | CGI:chr17:81527979-81529265 | promoter | 3.21e-01 | 4.54e-01 | -5.83e+00 | 5.56e-09 | 4.97e-08 | -1.33e-01 |
| CHOL | cg23164850 | chr17:81528322 | CGI:chr17:81527979-81529265 | promoter | 4.91e-01 | 6.37e-01 | -2.43e+00 | 1.50e-02 | 2.65e-02 | -1.46e-01 |
| Differentially expressed CpG sites between female tumor and female normal patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| BRCA | cg16201883 | chr17:81528927 | CGI:chr17:81527979-81529265 | promoter,exon,CDS,gene body | 5.92e-01 | 7.34e-01 | -7.47e+00 | 7.83e-14 | 2.61e-13 | -1.42e-01 |
| BRCA | cg00221012 | chr17:81528638 | CGI:chr17:81527979-81529265 | promoter,exon,CDS,gene body | 3.88e-01 | 5.27e-01 | -1.08e+01 | 3.64e-27 | 3.84e-26 | -1.39e-01 |
| KIRC | cg23164850 | chr17:81528322 | CGI:chr17:81527979-81529265 | promoter | 4.78e-01 | 3.56e-01 | 2.46e+00 | 1.38e-02 | 2.11e-02 | 1.21e-01 |
| KIRC | cg15774065 | chr17:81528294 | CGI:chr17:81527979-81529265 | promoter | 4.09e-01 | 2.92e-01 | 2.72e+00 | 6.54e-03 | 1.30e-02 | 1.18e-01 |
| HNSC | cg15774065 | chr17:81528294 | CGI:chr17:81527979-81529265 | promoter | 4.10e-01 | 2.92e-01 | 2.35e+00 | 1.86e-02 | 2.64e-02 | 1.18e-01 |
| COAD | cg01512532 | chr17:81528013 | CGI:chr17:81527979-81529265 | promoter | 5.73e-01 | 4.48e-01 | 2.16e+00 | 3.08e-02 | 3.54e-02 | 1.25e-01 |
| COAD | cg09084279 | chr17:81527980 | CGI:chr17:81527979-81529265 | promoter | 4.30e-01 | 3.28e-01 | 2.18e+00 | 2.96e-02 | 3.44e-02 | 1.02e-01 |
| BLCA | cg18919720 | chr17:81528309 | CGI:chr17:81527979-81529265 | promoter | 2.75e-01 | 4.52e-01 | -3.08e+00 | 2.09e-03 | 6.94e-03 | -1.77e-01 |
| BLCA | cg01512532 | chr17:81528013 | CGI:chr17:81527979-81529265 | promoter | 4.82e-01 | 6.41e-01 | -2.27e+00 | 2.33e-02 | 3.00e-02 | -1.59e-01 |
| BLCA | cg09084279 | chr17:81527980 | CGI:chr17:81527979-81529265 | promoter | 3.83e-01 | 5.42e-01 | -2.67e+00 | 7.64e-03 | 1.47e-02 | -1.60e-01 |
| BLCA | cg20932150 | chr17:81528242 | CGI:chr17:81527979-81529265 | promoter | 2.75e-01 | 3.96e-01 | -3.24e+00 | 1.20e-03 | 5.23e-03 | -1.20e-01 |
| BLCA | cg13700073 | chr17:81528298 | CGI:chr17:81527979-81529265 | promoter | 2.25e-01 | 3.37e-01 | -3.15e+00 | 1.61e-03 | 6.07e-03 | -1.12e-01 |
| LIHC | cg09084279 | chr17:81527980 | CGI:chr17:81527979-81529265 | promoter | 6.30e-01 | 7.74e-01 | -3.19e+00 | 1.41e-03 | 2.95e-03 | -1.44e-01 |
Top |
Exon skipping events with PSI in TCGA for FSCN2 |
| ∗Please access ExonSkipDB for exon skipping annotation. |
| Differentially expressed exon skipping events between male tumor and female tumor patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
| Differentially expressed exon skipping events between male tumor and male normal patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
| Differentially expressed exon skipping events between female tumor and female normal patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
Top |
RNA A-to-I editing events in TCGA for FSCN2 |
| ∗Please access CAeditome for RNA editing annotation. |
| Differentially expressed RNA editing events between male tumor and female tumor patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Differentially expressed RNA editing events between male tumor and male normal patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Differentially expressed RNA editing events between female tumor and female normal patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Protein coding RNA editing(s). |
| Editing Position | Variant Type | Gene Symbol | Transcript ID | NTchange | AAchange |
Top |
Sex-biased TF-Gene network for FSCN2 |
| TFs related to FSCN2. ∗The female-biased TF-gene edges were identified if Female_Edge_threshold>0.98 and Male_Edge_threshold<=0.98. ∗The male-biased TF-gene edges were identified if Male_Edge_threshold>0.98 and Female_Edge_threshold<=0.98. |
 |
| Cancer Type | TF | Target Gene | Male Edge Score | Male Edge Threshold | Female Edge Score | Female Edge Threshold | Type |
| PAAD | ZNF571 | FSCN2 | 3.16e+00 | 4.87e-03 | 4.10e+00 | 9.84e-01 | Female-biased |
| FSCN2 related gene. ∗Only the gene encode TF might with this result. ∗For more information please check Sex-biased TF-Coding gene network. |
Top |
Sex-biased RBP-ES network for FSCN2 |
| RBPs related to ES in FSCN2. ∗The female-biased RBP-ES edges were identified if Female_Edge_threshold>0.98 and Male_Edge_threshold<=0.98. ∗The male-biased RBP-ES edges were identified if Male_Edge_threshold>0.98 and Female_Edge_threshold<=0.98. |
| Cancer Type | RBP | Target ES | Male Edge Score | Male Edge Threshold | Female Edge Score | Female Edge Threshold | Type |
| FSCN2 related ES. ∗Only the gene encode RBP might with this result. ∗For more information please check Sex-biased RBP-ES network in cancer. |
Top |
Sex-biased CeRNA regulation of gene |
| Sex-biased CeRNA regulation of gene. |
| Gene ID | ceRNA(lncRNA-miRNA-mRNA) | Group | Cancer Type |
Top |
Sex-biased eQTL regulation of gene |
| Sex-biased eQTL regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| eQTL | Description |
| Male-specific eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Effect Score | FDR | Cancer Type | Biased Type |
| rs9909176 | chr17:73740704:T:C | - | 0.0399987940301608 | 0.0321466630867192 | LUAD | Female-baised eQTL |
| Female-specific eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Effect Score | FDR | Cancer Type | Biased Type |
| Opposite sex-biased eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Male Effect | Male FDR | Female Effect | Female FDR | Sex-biased Gene in Cancer | Cancer Type |
Top |
Sex-biased eQTM regulation of gene |
| Sex-biased eQTM regulation of gene (The figures only show the pairs with FDR<1e-5. For more information please check the below table). |
| eQTM | Description |
 | Gene ID: ENSG00000186765 |
| CpG Site: cg23164850 | |
| Position to Gene: promoter | |
| Male Effect: - | |
| Female Effect: -0.115014046456906 | |
 | Gene ID: ENSG00000186765 |
| CpG Site: cg00221012 | |
| Position to Gene: gene,exon,CDS,promoter | |
| Male Effect: - | |
| Female Effect: -0.107732169157977 |
| Male-specific eQTM regulation. |
| CpG Site | CpG Postion | Position to Gene | Effect Score | FDR | Cor.r | Cor.Pvalue | Cancer Type |
| Female-specific eQTM regulation. |
| CpG Site | CpG Postion | Position to Gene | Effect Score | FDR | Cor.r | Cor.Pvalue | Cancer Type |
| cg23164850 | chr17:81528322 | promoter | -0.115014046456906 | 7.61603831848987e-06 | -0.3465268482326419 | 1.3198606529332167e-08 | LUAD |
| cg00221012 | chr17:81528638 | gene,exon,CDS,promoter | -0.107732169157977 | 4.27157653363989e-05 | -0.32478803765998504 | 1.1236636617562068e-07 | LUAD |
| Opposite sex-biased eQTM regulation. |
| CpG Site | CpG Postion | CpG Island | Position to Gene | Male Effect | Male FDR | Female Effect | Female FDR | Male Cor | Male P-value | Female Cor | Female P-value | Sex-biased Coding Gene | Cancer Type |
Top |
Sex-biased sQTL regulation of gene |
| Sex-biased sQTL regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| sQTL | Description |
| Male-specific sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Effect Score | FDR | Cancer Type | Biased Type |
| Female-specific sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Effect Score | FDR | Cancer Type | Biased Type |
| Opposite sex-biased sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Male Effect | Male FDR | Female Effect | Female FDR | Cancer Type |
Top |
Sex-biased sQTM regulation of gene |
| Sex-biased sQTM regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| sQTM | Description |
| Male-specific sQTM regulation. |
| EX ID | Skipped Exon | CPG Site | CPG Position | Position to EX Events | Effect Score | FDR | Cor.r | Cor.Pvalue | ORF_anno | Cancer Type |
| Female-specific sQTM regulation. |
| EX ID | Skipped Exon | CPG Site | CPG Position | Position to EX Events | Effect Score | FDR | Cor.r | Cor.Pvalue | ORF_anno | Cancer Type |
| Opposite sex-biased sQTM regulation. |
| EX ID | EX Info | Skipped Exon | CPG Site | CPG Position | CPG Island | Position to EX Events | Male Effect | Male FDR | Female Effect | Female FDR | Male Correlation | Male P-value | Female Correlation | Female P-value | ORF_anno | Cancer Type |
Top |
Related disease information of FSCN2 |
| Diseases associated with this gene (DisGeNET). |
| Gene ID | Gene Symbol | Disease ID | Disease Name | Number of PMID | Source |
| ENSG00000186765 | FSCN2 | C1842816 | RETINITIS PIGMENTOSA 30 | 1 | CTD_human |
